CommercialPrior AuthMedium impact
Sebelipase Alfa (Kanuma®)
BCBS Tennessee·TN · Pediatrics, Internal Medicine, Genetics·Medical Policy
Effective date
Dec 1, 2026
We identified it
Sep 10, 2026
Summary
BlueCross BlueShield of Tennessee is establishing a new prior authorization and coverage policy for Sebelipase Alfa (Kanuma®) for treatment of Lysosomal Acid Lipase (LAL) deficiency. The policy requires documented enzyme assay or genetic confirmation of LAL deficiency, elevated ALT levels (≥1.5x upper limit of normal on two consecutive measurements), clinical disease signs, and prescriber specialization in metabolic/lysosomal storage disorders. Initial authorizations are granted for 12 months with continuation based on documented therapeutic response.
Action Required
By November 15, 2026: Billing team must implement prior authorization workflow for Sebelipase Alfa (Kanuma®) claims in the billing system. Create a pre-authorization checklist requiring: (1) LAL deficiency confirmation via enzyme assay or genetic testing documentation, (2) ALT lab values ≥1.5x upper limit of normal from two separate measurements at least one week apart, and (3) clinical symptom documentation (hepatomegaly, splenomegaly, failure to thrive, or dyslipidemia). Update provider templates and claim submission processes to identify prescriber specialty (metabolic disease/lysosomal storage disorder specialist required). Configure system to allow 12-month authorization periods for initial requests and continuation requests requiring evidence of therapeutic response. Communicate to all pediatric, internal medicine, and genetics providers that Kanuma claims submitted without prior authorization or missing required documentation will be denied.